MediciNova is a La Jolla, California drug developer working on experimental treatments for diseases such as multiple sclerosis and ALS. MNOV reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 17 | Roth Capital | Initiated | Buy | |
| Mar 23 | Maxim Group | Reinstated | Buy |
Seasonality
How MNOV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in MNOV in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNOV is in one of them and how their past MNOV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MNOV in an article yet. Here's the latest on the wider market.
About Medicinova
MediciNova is a biopharmaceutical company based in La Jolla, California. It develops drug candidates for serious diseases that lack adequate treatment options. Its main candidates are MN-166, also called ibudilast, which is being studied for conditions such as progressive multiple sclerosis and amyotrophic lateral sclerosis, and MN-001, also called tipelukast, which is being studied for fibrotic and metabolic disorders such as fatty liver disease. The company's commercial focus is the United States market.
- Headquarters
- La Jolla, CA